NASDAQ:REPH - Recro Pharma Stock Price, Forecast & News

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Recro Pharma Inc (NASDAQ:REPH) posted its quarterly earnings results on Friday, November, 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The specialty pharmaceutical company earned $25.26 million during the quarter, compared to analyst estimates of $19.83 million. View Recro Pharma's Earnings History.

Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Recro Pharma.

3 analysts have issued 1-year price objectives for Recro Pharma's shares. Their forecasts range from $7.50 to $20.00. On average, they anticipate Recro Pharma's share price to reach $15.50 in the next year. This suggests that the stock has a possible downside of 8.2%. View Analyst Price Targets for Recro Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

News articles about REPH stock have trended very negative recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Recro Pharma earned a news impact score of -3.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Recro Pharma.

Recro Pharma saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,090,000 shares, a decrease of 15.5% from the January 15th total of 1,290,000 shares. Based on an average daily volume of 341,900 shares, the days-to-cover ratio is presently 3.2 days. Currently, 5.7% of the shares of the stock are short sold. View Recro Pharma's Current Options Chain.

Some companies that are related to Recro Pharma include Nabriva Therapeutics (NBRV), ZEALAND PHARMA/S (ZEAL), Theravance Biopharma (TBPH), Madrigal Pharmaceuticals (MDGL), Dicerna Pharmaceuticals (DRNA), Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Intra-Cellular Therapies (ITCI), Zogenix (ZGNX), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT) and Athenex (ATNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Recro Pharma investors own include Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Progenics Pharmaceuticals (PGNX), Flexion Therapeutics (FLXN), TG Therapeutics (TGTX), Verastem (VSTM), Viking Therapeutics (VKTX) and Corbus Pharmaceuticals (CRBP).

Recro Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.48%), Broadfin Capital LLC (3.17%), Panagora Asset Management Inc. (2.10%), State Street Corp (1.79%), Geode Capital Management LLC (1.26%) and Prudential Financial Inc. (1.26%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood and Healthcare Master Fun Broadfin. View Institutional Ownership Trends for Recro Pharma.

REPH stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Oxford Asset Management LLP, Essex Investment Management Co. LLC, Monarch Partners Asset Management LLC, Penn Capital Management Co. Inc., Walthausen & Co. LLC, Goldman Sachs Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Recro Pharma.

REPH stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Calamos Advisors LLC, Renaissance Technologies LLC, EAM Global Investors LLC, Prudential Financial Inc., EAM Investors LLC, Russell Investments Group Ltd. and Panagora Asset Management Inc.. View Insider Buying and Selling for Recro Pharma.

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REPH stock can currently be purchased for approximately $16.88.

Recro Pharma has a market capitalization of $383.68 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.

The official website for Recro Pharma is http://www.recropharma.com/.

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]